However, less emphasis has been paid to documenting the imaging and clinical aspects of less common sites of prostate cancer metastases, such as the adrenal gland.68Ga-PSMA in prostate cancer is increasingly used to detect disease burden and metastasis because the results of68Ga-PSMA affect clinical practice and treatment management in about half of the patients. This evidence concerns the gene FOLH1 and prostate cancer.